NOWDiagnostics Partners With Labcorp To Expand Access To First FDA-Authorized OTC Syphilis Test In The U.S.; First To Know Syphilis Test To Be Available In Clinical And Hospital Settings By Late 2024, With Direct Patient Access Via Labcorp OnDemand In 2025
Portfolio Pulse from Benzinga Newsdesk
NOWDiagnostics has partnered with Labcorp to expand access to the first FDA-authorized over-the-counter syphilis test in the U.S. The test will be available in clinical and hospital settings by late 2024, with direct patient access via Labcorp OnDemand in 2025.
October 16, 2024 | 12:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Labcorp partners with NOWDiagnostics to offer the first FDA-authorized OTC syphilis test in the U.S., enhancing its product offerings and potentially increasing its market share in the diagnostics sector.
The partnership with NOWDiagnostics to offer an FDA-authorized OTC syphilis test positions Labcorp as a leader in innovative healthcare solutions. This could enhance its market presence and attract more customers, potentially boosting its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80